Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

MACK Merrimack Pharmaceuticals Inc

15,1575

0,00 (0,00%)

Nach Börsenschluss

Zuletzt aktualisiert: 02:00:00

Verzögert um 15 Minuten

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Merrimack Pharmaceuticals Charts.

Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Merrimack Pharmaceuticals Charts.

News Merrimack Pharmaceuticals Inc

Form 15-12G - Securities registration termination [Section 12(g)]
Montag 20 Mai 2024 (2 Tage vor) • Edgar (US Regulatory)

Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities
Freitag 10 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Freitag 10 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Freitag 10 Mai 2024 (2 Wochen vor) • Business Wire

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Donnerstag 9 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 9 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
Donnerstag 9 Mai 2024 (2 Wochen vor) • Business Wire

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
Dienstag 30 April 2024 (3 Wochen vor) • Business Wire

Merrimack Receives $225 Million Milestone Payment from Ipsen
Mittwoch 27 März 2024 (2 Monate vor) • Business Wire

Form 425 - Prospectuses and communications, business combinations
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Merrimack Reports Full Year 2023 Financial Results
Donnerstag 7 März 2024 (2 Monate vor) • Business Wire

Weitere Merrimack Pharmaceuticals Inc News-Artikel

Ellect Holdings

Paternoster Resources

Two Harbors Investment

Four Seasons Education C...

Vontobel Financial Produ...

Spdr Europe Val

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen